Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $3.0 million.

  • Pharma's Operating Expenses rose 5311.54% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 1363.82%. This contributed to the annual value of $8.1 million for FY2025, which is 2318.62% down from last year.
  • Per Pharma's latest filing, its Operating Expenses stood at $3.0 million for Q3 2025, which was up 5311.54% from $2.1 million recorded in Q2 2025.
  • Pharma's 5-year Operating Expenses high stood at $6.6 million for Q1 2022, and its period low was $1.6 million during Q1 2025.
  • Moreover, its 5-year median value for Operating Expenses was $2.6 million (2024), whereas its average is $2.9 million.
  • In the last 5 years, Pharma's Operating Expenses soared by 15769.68% in 2021 and then crashed by 4281.57% in 2024.
  • Pharma's Operating Expenses (Quarter) stood at $2.4 million in 2021, then dropped by 2.74% to $2.4 million in 2022, then surged by 31.55% to $3.1 million in 2023, then crashed by 36.7% to $2.0 million in 2024, then surged by 51.26% to $3.0 million in 2025.
  • Its Operating Expenses stands at $3.0 million for Q3 2025, versus $2.1 million for Q2 2025 and $1.6 million for Q1 2025.